Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olga Mulas

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
International Journal of Cardiology|April 29, 2019
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary preventionGiovanni Caocci, Olga Mulas, Massimiliano Bonifacio, et al.
Hemasphere|December 31, 2025
Health-related quality of life and symptom profile of patients with <i>BCR::ABL1</i>-negative myeloproliferative neoplasms: Real-world evidence from the GIMEMA-PROPHECY observational studyGiovanni Caocci, Alessandro Costa, Francesca Palandri, et al.
Annals of Hematology|November 27, 2023
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinibOlga Mulas, Elisabetta Abruzzese, Luigiana Luciano, et al.
Cancer|October 15, 2025
Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS studyAnna Sicuranza, Paola Pacelli, Adele Santoni, et al.
Hematological Oncology|March 21, 2019
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chartGiovanni Caocci, Olga Mulas, Elisabetta Abruzzese, et al.
Frontiers in Oncology|June 15, 2018
Residual Peripheral Blood CD26<sup>+</sup> Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free RemissionMonica Bocchia, Anna Sicuranza, Elisabetta Abruzzese, et al.
Hematological Oncology|July 1, 2020
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinibOlga Mulas, Giovanni Caocci, Mario Annunziata, et al.
Leukemia Research|June 3, 2026
Association of hypomethylating agents + venetoclax in the real-life treatment of Myeloproliferative Neoplasms in blastic phaseRoberto Latagliata, Novella Pugliese, Dorela Lame, et al.
International Journal of Cardiology|November 13, 2019
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitorsGiovanni Caocci, Olga Mulas, Mario Annunziata, et al.
Blood Cancer Journal|June 10, 2020
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML studyGiovanni Caocci, Olga Mulas, Isabella Capodanno, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
International Journal of Cardiology|April 29, 2019
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary preventionGiovanni Caocci, Olga Mulas, Massimiliano Bonifacio, et al.
Hemasphere|December 31, 2025
Health-related quality of life and symptom profile of patients with <i>BCR::ABL1</i>-negative myeloproliferative neoplasms: Real-world evidence from the GIMEMA-PROPHECY observational studyGiovanni Caocci, Alessandro Costa, Francesca Palandri, et al.
Annals of Hematology|November 27, 2023
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinibOlga Mulas, Elisabetta Abruzzese, Luigiana Luciano, et al.
Cancer|October 15, 2025
Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS studyAnna Sicuranza, Paola Pacelli, Adele Santoni, et al.
Hematological Oncology|March 21, 2019
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chartGiovanni Caocci, Olga Mulas, Elisabetta Abruzzese, et al.
Frontiers in Oncology|June 15, 2018
Residual Peripheral Blood CD26<sup>+</sup> Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free RemissionMonica Bocchia, Anna Sicuranza, Elisabetta Abruzzese, et al.
Hematological Oncology|July 1, 2020
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinibOlga Mulas, Giovanni Caocci, Mario Annunziata, et al.
Leukemia Research|June 3, 2026
Association of hypomethylating agents + venetoclax in the real-life treatment of Myeloproliferative Neoplasms in blastic phaseRoberto Latagliata, Novella Pugliese, Dorela Lame, et al.
International Journal of Cardiology|November 13, 2019
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitorsGiovanni Caocci, Olga Mulas, Mario Annunziata, et al.
Blood Cancer Journal|June 10, 2020
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML studyGiovanni Caocci, Olga Mulas, Isabella Capodanno, et al.
Pageof 6